A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
Myelodysplastic Syndromes
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 19, 2024. Captured 2026-09-09.
The latest version of the WHO pathological classification system identifies patients with therapy-related MDS or AML and places them in the same category as “therapy-related myeloid neoplasms.” This group of disorders evolves in patients who were previously treated with chemotherapy or radiation therapy for other cancers and in whom there is a clinical suspicion that the prior therapy caused the myeloid neoplasm. Classic chemotherapy agents associated with these disorders include alkylating agents, topoisomerase inhibitors, and purine nucleoside analogues.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 19, 2024. Captured 2026-09-09.
Therapies for myelodysplastic syndromes (MDS) are initiated in patients with a shorter predicted survival or in patients with clinically significant cytopenias. The impact of most MDS therapies on survival remains unproven.
Treatment options:
Supportive care.
Sources: Supportive care
Disease-modifying agents.
Sources: Disease-modifying agents
Immunosuppressive therapy.
Sources: Immunosuppressive therapy
DNA methyltransferase inhibitors.
Sources: DNA methyltransferase inhibitors
Acute myeloid leukemia (AML) induction-type chemotherapy.
Sources: Acute myeloid leukemia (AML) induction-type chemotherapy
Allogeneic hematopoietic stem cell transplant (HSCT).
Sources: Allogeneic hematopoietic stem cell transplant (HSCT)
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 19, 2024. Captured 2026-09-09.
The mainstay of treatment for MDS has traditionally been supportive care, particularly for patients with symptomatic cytopenias or who are at high risk of infection or bleeding.[1,2] Transfusions are reserved for the treatment of active bleeding; many centers offer prophylactic platelet transfusions for patients with platelet counts lower than 10,000/mm3. Anemia should be treated with red-cell transfusions to avoid symptoms. For more information, see Fatigue.
No prospective trials have demonstrated the benefit of prophylactic use of myeloid growth factors in asymptomatic neutropenic MDS patients. Similarly, the use of prophylactic antibiotics in such patients is of uncertain benefit. While appropriate use of antibiotics in febrile patients is standard clinical practice, the benefit of myeloid growth factors in such settings is unknown.
The use of erythropoiesis-stimulating agents (ESAs) may improve anemia. The likelihood of response to exogenous erythropoietin administration depends on the pretreatment serum erythropoietin level and baseline transfusion needs.
A meta-analysis summarized the data on erythropoietin in 205 patients with MDS from 17 studies. Responses were most likely in patients who were anemic but who did not yet require a transfusion, patients who did not have ring sideroblasts, and patients who had a serum erythropoietin level lower than 200 IU/L.[3] Effective treatment requires substantially higher doses of erythropoietin than are used for other indications; the minimum effective dose studied is 60,000 IU per week.[4] The use of high-dose darbepoetin (300 µg/dose weekly or 500 µg/dose every 2–3 weeks) has been reported to produce a major erythroid response rate of almost 50% in patients whose endogenous erythropoietin level was lower than 500 mIU/mL.[5,6] Most studies discontinued ESAs in patients who failed to show hematologic improvement after 3 to 4 months of therapy. Average response duration is approximately 2 years.[7]
One decision model found that the likelihood of responding to growth factors was higher in patients with a low serum erythropoietin level (<500 IU/L) and low transfusion needs (<2 units of packed red blood cells every month), but growth factors were rarely effective in patients with a high erythropoietin level and high transfusion needs.[8] Some patients with poor response to erythropoietin alone may have improved response with the addition of low doses of granulocyte colony-stimulating factor (G-CSF) (0.5–1.0 µg/kg/day).[9-11] Rates of response to the combination treatment vary with classification, with responses more likely in patients with refractory anemia and ring sideroblasts (RARS) and less likely in patients with excess blasts.[7] Patients with RARS are unlikely to respond to erythropoietin alone.[3]
The availability of the oral iron-chelating agent deferasirox has led to its widespread use in patients with MDS. While some consensus panels advocate prophylactic iron chelation in patients with ongoing transfusion needs and substantial transfusion history, the impact of iron chelation on survival and disease progression is unknown.[12]
Sources: 12
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 19, 2024. Captured 2026-09-09.
Lower-risk patients (conventionally defined as International Prognostic Scoring System (IPSS) low-risk and intermediate-1–risk groups) who have failed to respond or have ceased responding to ESAs may be treated with one of several disease-modifying agents. The impact of this practice on survival in lower-risk patients is unknown. Whether these drugs should be used following an ESA failure or as up-front therapy has never been determined. In contrast, in higher-risk patients, azacitidine has been shown to improve survival. For more information, see the DNA methyltransferase inhibitors section.
Sources: DNA methyltransferase inhibitors
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 19, 2024. Captured 2026-09-09.
The U.S. Food and Drug Administration (FDA) approved lenalidomide for the treatment of lower-risk, transfusion-dependent patients with MDS who harbor a del(5q) cytogenic abnormality. In a phase II registration study of 148 transfusion-dependent low-risk and intermediate-1–risk patients with del(5q) chromosomal abnormalities (alone, or associated with other abnormalities), lenalidomide induced transfusion independence in 67%, with a median time to response of 4 to 5 weeks.[13] The median duration of transfusion independence had not been reached after a median of 104 weeks of follow-up. Of 62 evaluable patients, 38 patients developed complete cytogenetic remission.
Sources: 13
Lenalidomide administration is limited by dose-limiting neutropenia and thrombocytopenia.[14][Level of evidence C3] Treatment-related thrombocytopenia also correlated with cytogenetic responses, emphasizing the importance of successful suppression of the del(5q) clone with lenalidomide to achieve meaningful responses.[15]
Sources: 14 · Level of evidence C3 · 15
A subsequent phase III study randomly assigned lower-risk del(5q) MDS patients to receive placebo and lenalidomide at either 5 mg daily for 28 days or 10 mg daily for 21 days of a 28-day cycle.[16] Transfusion independence responses lasting longer than 6 months occurred in 43% to 52% of subjects treated on the lenalidomide arms, compared with 6% of controls. The cytogenetic response rate was 25% to 50% on the active treatment arms, and the 3-year risk of AML transformation was 25%.
Sources: 16
Lenalidomide has limited activity in lower-risk, red blood cell transfusion–dependent patients in MDS who do not harbor the del(5q) lesion. In a phase II study similar in design to the registration study, 56 of 215 patients (26%) achieved transfusion independence.[17] Median duration of response was 41 weeks (range, 8–136 weeks). Grade 3 or 4 myelosuppression occurred in only 20% to 25% of patients and, unlike for del(5q) patients, was not associated with subsequent attainment of a transfusion independence response to therapy.
Sources: 17
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 19, 2024. Captured 2026-09-09.
Antithymocyte globulin (ATG) has shown activity in MDS patients in several small series. The National Heart, Lung, and Blood Institute conducted a phase II trial including 25 MDS patients with less than 20% blasts. Of all the patients studied, 11 (or 44%) responded and became transfusion-independent after ATG (three complete responses, six partial responses, and two minimal responses).[18] Multivariate analysis identified HLA-DR-15 (phenotype) expression, briefer period of red cell transfusion dependence, and younger age as predictors of response to ATG.[19] One study used alemtuzumab to treat a heavily preselected population of lower-risk MDS patients, in whom the response rate was 80%.[20]
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 19, 2024. Captured 2026-09-09.
The nucleoside analogues azacitidine and decitabine are inhibitors of DNA methyltransferase. Both drugs require prolonged administration before benefits are seen. The median number of cycles required to see first hematologic response to azacitidine was 3; 90% of responders showed response by 6 cycles; and the median number of cycles of decitabine required to see first response was 2.2.[21] Azacitidine received FDA approval based on the results of a randomized trial that was not designed to study survival.[22]
A phase III randomized controlled trial (AZA PH GL 2003 CL 001 [NCT00071799]) of azacitidine versus other regimens, including low-dose cytarabine, AML-type remission induction chemotherapy, or best supportive care, was limited to patients with higher-risk MDS subtypes (IPSS intermediate-2 risk and high risk).[17] The median and 2-year overall survival (OS) favored the azacitidine arm, at 24 months versus 16 months (P = .0001) and 51% versus 26% (P < .0001), respectively.[17][Level of evidence A1] The FDA-approved azacitidine dose schedule used in this study (75 mg/m2 per day for 7 consecutive days) has proven inconvenient to some practitioners. A community-based study has suggested that alternate dosing schedules may provide similar hematologic benefits; however, the impact of such dosing schedules on survival is not known.[23]
Sources: AZA PH GL 2003 CL 001 · 17 · 17 · Level of evidence A1 · 23
While the azacitidine congener decitabine demonstrated similar activity in phase II trials, two randomized trials of decitabine versus supportive care failed to show a survival benefit.[21,24] Both decitabine studies used the FDA-approved dose schedule (15 mg/m2 every 8 hours for nine doses). In the European phase III study in higher-risk patients, median OS was similar for patients in both the decitabine and best supportive care arms, at 10.1 months versus 8.5 months, respectively (P = .38). A combined OS and delay in AML transformation end point was 8.8 months versus 6.1 months, respectively (P = .24).[25][Level of evidence A1]
Sources: 21 · 24 · 25 · Level of evidence A1
Decitabine can be given as daily intravenous or subcutaneous infusions at doses that differ from the original labeled schedule, with hematologic response rates that appear comparable to the phase III study.[26,27]
Both of these drugs have been approved for refractory anemia, RARS (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, and refractory anemia with excess blasts in transformation. However, the highest response rates and levels of evidence have been generated in trials in which patients with higher-risk MDS (IPSS risk groups of intermediate-2 or high) were treated.[28] In lower-risk patients, response rates appear similar to those in higher-risk patients, although the survival benefit is unknown. The use of these drugs in low-risk patients may preclude their subsequent use upon disease progression.
Sources: 28
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 19, 2024. Captured 2026-09-09.
Induction chemotherapy typically used to treat AML may be used to treat patients with higher-risk MDS with excess blasts.[31] Low-dose cytarabine has benefitted some patients; however, this treatment was associated with a higher infection rate when compared with observation in a randomized trial. No difference in time to progression or OS was observed for patients treated with low-dose cytarabine or supportive care.
Sources: 31
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 19, 2024. Captured 2026-09-09.
Allogeneic HSCT is the only potentially curative treatment for MDS. Retrospective data suggest cure rates in selected patients ranging from 30% to 60%; outcomes varied with IPSS score at time of transplant, with inferior survival in patients with higher IPSS scores.[32][Level of evidence C3] The role of cytoreductive therapy in reducing the blast percentage before HSCT remains uncertain. Outcomes may not be as good for patients with treatment-related MDS (5-year disease-free survival rate of 8% to 30%).[33]
Sources: 32 · Level of evidence C3 · 33
Although HSCT represents the only treatment modality with curative potential, the relatively high morbidity and mortality of this approach limits its use. A decision analysis predating approval of azacitidine, in patients with a median age younger than 50 years, suggested optimal survival when transplant was delayed until disease progression for lower-risk patients but implemented at diagnosis for higher-risk patients.[34]
Sources: 34
Allogeneic stem cell transplant with reduced-intensity conditioning (RIC) has extended transplant as a possible modality for treatment of older patients.[35] In a retrospective analysis of 1,333 patients aged 50 years or older (median, 56 years) who underwent allogeneic transplants for MDS using HLA-matched sibling and unrelated donors, 62% of the patients received RIC HSCT, and the others received standard-dose HSCT. On multivariate analysis, use of RIC and advanced disease stage at transplant were associated with increased relapse (hazard ratio [HR] of 1.44 and 1.51, respectively).[35][Level of evidence C3] The predictors of non-relapse mortality included advanced disease stage (HR, 1.43), use of an unrelated donor, and standard-dose HSCT (HR, 1.27). The 4-year OS rate was similar in both groups (30% after myeloablative conditioning vs. 32% in RIC.[35]
Sources: 35 · 35 · Level of evidence C3 · 35
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 19, 2024. Captured 2026-09-09.
In the absence of prospective data, therapy-related myeloid neoplasms are treated similarly to de novo MDS.
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 19, 2024. Captured 2026-09-09.
Lack of response or progression after the use of erythropoiesis-stimulating agents is not considered relapsed or refractory myelodysplastic syndromes (MDS).
With the exception of the use of lenalidomide for low-risk patients with abnormalities of chromosome 5, there are no clinical trials informing the appropriate selection of therapies for patients with specific subtypes of MDS. Patients who have ceased to respond or did not respond to one therapy are frequently offered another from the therapies described in the previous sections. Retrospective data suggest that patients who do not respond or have ceased responding to DNA methyltransferase inhibitors have a median survival of only 4 to 6 months.[1,2] Patients with relapses should be considered for enrollment in clinical trials.
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
Anything that increases a person's chance of getting a disease is called a risk factor. Not every person with one or more of these risk factors will develop myelodysplastic syndromes, and they will develop in people who don't have any known risk factors. Talk with your doctor if you think you may be at risk. Risk factors for myelodysplastic syndromes include the following:
Sources: risk factor
Past treatment with chemotherapy or radiation therapy for cancer.
Sources: chemotherapy · radiation therapy · cancer
Being exposed to certain chemicals, including tobacco smoke, pesticides, fertilizers, and solvents such as benzene.
Sources: chemicals · tobacco · pesticides · solvents · benzene
Being exposed to heavy metals, such as mercury or lead.
Sources: mercury
The cause of myelodysplastic syndromes in most patients is not known.
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
The prognosis and treatment options depend on the following:
Sources: prognosis
The number of blast cells in the bone marrow.
Whether one or more types of blood cells are affected.
Whether the patient has signs or symptoms of anemia, bleeding, or infection.
Whether the patient has a low or high risk of leukemia.
Certain changes in the chromosomes.
Whether the myelodysplastic syndrome occurred after chemotherapy or radiation therapy for cancer.
The patient's age and general health.
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
There are different types of treatment for patients with myelodysplastic syndromes.
Treatment for myelodysplastic syndromes includes supportive care, drug therapy, and stem cell transplant.
The following types of treatment are used:
The following types of treatment are used:
Supportive care
Drug therapy
Chemotherapy with stem cell transplant
New types of treatment are being tested in clinical trials.
Treatment for myelodysplastic syndromes may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their treatment.
Follow-up tests may be needed.
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
Different types of treatment are available for patients with myelodysplastic syndromes. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: myelodysplastic syndromes · standard · clinical trials · research study · cancer
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
Patients with a myelodysplastic syndrome who have symptoms caused by low blood counts are given supportive care to relieve symptoms and improve quality of life. Drug therapy may be used to slow progression of the disease. Certain patients can be cured with aggressive treatment with chemotherapy followed by stem cell transplant using stem cells from a donor.
Sources: symptoms · blood counts · supportive care · quality of life · Drug therapy · progression · cured · chemotherapy · stem cell transplant · stem cells · donor
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
Supportive care is given to lessen the problems caused by the disease or its treatment. Supportive care may include the following:
Transfusion therapy Transfusion therapy (blood transfusion) is a method of giving red blood cells, white blood cells, or platelets to replace blood cells destroyed by disease or treatment. A red blood cell transfusion is given when the red blood cell count is low and signs or symptoms of anemia, such as shortness of breath or feeling very tired, occur. A platelet transfusion is usually given when the patient is bleeding, is having a procedure that may cause bleeding, or when the platelet count is very low. Patients who receive many blood cell transfusions may have tissue and organ damage caused by the buildup of extra iron. These patients may be treated with iron chelation therapy to remove the extra iron from the blood.
Sources: therapy · blood transfusion · red blood cells · white blood cells · platelets · cells · signs · anemia · platelet · tissue · organ · iron · chelation · iron
Erythropoiesis-stimulating agents Erythropoiesis-stimulating agents (ESAs) may be given to increase the number of mature red blood cells made by the body and to lessen the effects of anemia. Sometimes granulocyte colony-stimulating factor (G-CSF) is given with ESAs to help the treatment work better.
Sources: Erythropoiesis-stimulating agents · granulocyte colony-stimulating factor
Antibiotic therapy Antibiotics may be given to fight infection.
Sources: Antibiotics · infection
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
Lenalidomide Patients with myelodysplastic syndrome associated with an isolated del(5q) chromosome abnormality who need frequent red blood cell transfusions may be treated with lenalidomide. Lenalidomide is used to lessen the need for red blood cell transfusions.
Sources: chromosome · abnormality · lenalidomide
Immunosuppressive therapy Antithymocyte globulin (ATG) works to suppress or weaken the immune system. It is used to lessen the need for red blood cell transfusions.
Sources: Antithymocyte globulin · immune system
Azacitidine and decitabine Azacitidine and decitabine are used to treat myelodysplastic syndromes by killing cells that are dividing rapidly. They also help genes that are involved in cell growth to work the way they should. Treatment with azacitidine and decitabine may slow the progression of myelodysplastic syndromes to acute myeloid leukemia.
Sources: Azacitidine · decitabine · genes · acute myeloid leukemia
Chemotherapy used in acute myeloid leukemia (AML) Patients with a myelodysplastic syndrome and a high number of blasts in their bone marrow have a high risk of acute leukemia. They may be treated with the same chemotherapy regimen used in patients with acute myeloid leukemia.
Sources: blasts · bone marrow · regimen
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
Chemotherapy is given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.
Sources: blood · bone marrow · infusion
This treatment may not work as well in patients whose myelodysplastic syndrome was caused by past treatment for cancer.
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
The treatment of myelodysplastic syndromes may include the following:
Sources: myelodysplastic syndromes
Supportive care with one or more of the following:
Sources: Supportive care
Supportive care with one or more of the following:
Transfusion therapy.
Sources: Transfusion · therapy
Erythropoiesis-stimulating agents.
Sources: Erythropoiesis-stimulating agents
Antibiotic therapy.
Sources: Antibiotic
Treatments to slow progression to acute myeloid leukemia (AML):
Sources: progression · acute myeloid leukemia
Immunosuppressive therapy.
Sources: Immunosuppressive therapy
Azacitidine and decitabine.
Sources: Azacitidine · decitabine
Chemotherapy used in acute myeloid leukemia.
Sources: Chemotherapy
Chemotherapy with stem cell transplant.
Sources: stem cell transplant
Patients who were treated in the past with chemotherapy or radiation therapy may develop myeloid neoplasms related to that therapy. Treatment options are the same as for other myelodysplastic syndromes.
Sources: radiation therapy · myeloid · neoplasms
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Myelodysplastic Syndromes Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: October 4, 2024. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
There is no standard treatment for refractory or relapsed myelodysplastic syndromes. Patients whose cancer does not respond to treatment or has come back after treatment may want to take part in a clinical trial.
Sources: standard treatment · refractory · relapsed · myelodysplastic syndromes · cancer · respond · clinical trial
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Myelodysplastic Syndromes
ClinicalTrials.gov recordChronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts,...
ClinicalTrials.gov recordMyelodysplastic Syndrome
ClinicalTrials.gov recordMyelodysplastic Syndrome, MDS
ClinicalTrials.gov recordMyelodysplastic Syndromes
ClinicalTrials.gov recordMyelodysplastic Syndromes
ClinicalTrials.gov recordMyelodysplastic Syndromes
ClinicalTrials.gov recordChronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Nonmalignant Neoplasm, Unspecified Adult Solid...
ClinicalTrials.gov recordLeukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
ClinicalTrials.gov recordLeukemia, Myelodysplastic Syndromes
ClinicalTrials.gov recordLeukemia, Myelodysplastic Syndromes
ClinicalTrials.gov recordMyeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
ClinicalTrials.gov recordCongenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia, Myelodysplastic Syndromes, Severe Congenital Neutropenia
ClinicalTrials.gov recordLeukemia, Myelodysplastic Syndromes
ClinicalTrials.gov recordLeukemia, Myelodysplastic Syndromes
ClinicalTrials.gov recordMyelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Myeloma, Lymphoma
ClinicalTrials.gov recordLeukemia, Myelodysplastic Syndromes
ClinicalTrials.gov recordLeukemia, Myelodysplastic Syndromes
ClinicalTrials.gov recordGraft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
ClinicalTrials.gov recordLeukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
ClinicalTrials.gov recordGraft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
ClinicalTrials.gov recordChronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
ClinicalTrials.gov recordLeukemia, Myelodysplastic Syndromes
ClinicalTrials.gov recordLeukemia, Myelodysplastic Syndromes
ClinicalTrials.gov recordLeukemia, Myelodysplastic Syndromes
ClinicalTrials.gov recordGraft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
ClinicalTrials.gov recordCancer, Chronic Myelomonocytic Leukemia
ClinicalTrials.gov recordLeukemia, Lymphoma, Myelodysplastic Syndromes
ClinicalTrials.gov recordLeukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
ClinicalTrials.gov recordGraft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
ClinicalTrials.gov recordLeukemia, Lymphoma, Malnutrition, Myelodysplastic Syndromes, Unspecified Childhood Solid Tumor, Protocol Specific, Weight Changes
ClinicalTrials.gov recordLeukemia, Myelodysplastic Syndromes
ClinicalTrials.gov recordChronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With...
ClinicalTrials.gov recordAnemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low to Intermediate-1 MDS, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
ClinicalTrials.gov recordMyelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
ClinicalTrials.gov recordMyelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
ClinicalTrials.gov recordMyelodysplastic Syndromes
ClinicalTrials.gov recordMyelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
ClinicalTrials.gov recordMyelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
ClinicalTrials.gov recordMyelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
ClinicalTrials.gov recordMyelodysplastic Syndromes (MDS)
ClinicalTrials.gov recordMyelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency, Liver Disease, Neoplasms
ClinicalTrials.gov recordMyelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
ClinicalTrials.gov recordMyelodysplastic Syndromes
Treatment of Relapsed or Refractory MDS
Relapsed or refractory Myelodysplastic Syndromes (MDS) For the treatment of adult patients with relapsed or refractory myelodysplastic syndromes ( 1.3 ).
1.3 Relapsed or Refractory Myelodysplastic Syndromes TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as...
ALVAIZ is a thrombopoietin receptor agonist indicated: for the treatment of thrombocytopenia in adult and pediatric patients 6 years and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient...
DailyMed labelAzacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of adult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed...
DailyMed labelDecitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia,...
DailyMed labelFERRIPROX Oral Solution is indicated for the treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. FERRIPROX Oral Solution is...
DailyMed labelFERRIPROX Tablets are indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. Limitation s of Use • Safety and...
DailyMed labelNplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy....
DailyMed labelPROMACTA is a thrombopoietin receptor agonist indicated: for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient...
DailyMed labelREBLOZYL is an erythroid maturation agent indicated for the treatment of: • Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions ( 1.1 ). • Anemia without previous erythropoiesis...
DailyMed label1. INDICATIONS AND USAGE RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks...
DailyMed label